Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Metabolic Dysfunction-Associated Liver Diseases
In what scenario would you opt to perform an MRI-PDFF in a patient with MASLD/MASH or in whom you suspect has this? Why would you opt for this over a Fibroscan or other NILDA?
Related Questions
In what kind of patient scenario would you consider testing for inherited disorders of lipid metabolism in the evaluation of a patient with MASLD? What are you looking for clinically and in their workup and how do you proceed?
How do you incorporate other pharmacologic bariatric/appetite suppressants in the context of their clinical care plan for MASLD?
What is your approach to the use of lipoprotein(a) as part of the cardiometabolic profile of a patient suspected to have or with MASLD/MASH?
In patients with Met-ALD, would you still offer the same therapeutic/pharmacologic treatments (ex: GIP/GLP-1 agonists, Resmetirom, ex) for management of their disease as in a "pure" MASLD patient?
What testing do you utilize to decide a patient's candidacy for Resmetirom therapy?
How does managing a patient with concomitant alcohol related liver disease impact your choice of therapies?
In patients with Met-ALD, how do you approach their treatment plan?
Is the Enhanced Liver Fibrosis (ELF) test superior to the FIB-4 test in the diagnosis of MASLD?
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
What clinical, imaging, or serologic markers would be an indication to you to stop GLP-1 therapy for management of MASLD?
